BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Hong Kong Strengthens Position as Global Healthcare Investment Hub with Over 1,000 Business Meetings at ASGH and Medical Fair

Over 1,000 investment and business matching meetings lined up underscoring Hong Kong's role as a healthcare investment hub - ASGH brought toget...

May 29, 2025 | News

United Imaging and HKSH Medical Group Unite to Set New Standards in Medical Imaging Excellence

United Imaging and HKSH Medical Group announced on Monday the signing of a Memorandum of Understanding (MOU), marking a significant step forward in fosteri...

May 28, 2025 | News

HKSH Medical Group Strengthens Global Healthcare Partnerships with New Collaboration on Imaging Innovation

The HKSH Medical Group (HKSH) has for over a century been committed to acquiring the state-of-the-art, world-class technology and facilities to deliver exc...

May 28, 2025 | News

Antengene and MSD Enter Global Clinical Collaboration to Evaluate ATG-022 and KEYTRUDA® Combo in Solid Tumors

Antengene Corporation Limited , a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercial...

May 21, 2025 | News

AIM Vaccine Secures PRC Clinical Approval for mRNA Shingles Vaccine, Strengthening Global Race in Next-Gen Immunization

While global giants like Moderna and BioNTech apply mRNA technology to broader disease markets, PRC's mRNA frontrunner is keeping pace. AIM Vaccine (06660....

May 20, 2025 | News

Viva Biotech Unveils Advanced AI-Driven Drug Discovery Platform, Pioneering a New Era of Intelligent Therapeutics

Artificial intelligence has rapidly evolved from academic theory into a transformative force in pharmaceutical R&D. From early QSAR models to neur...

May 16, 2025 | News

China Grants Full Approval to Everest Medicines’ NEFECON® as First and Only Etiological Treatment for IgA Nephropathy

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, a...

May 07, 2025 | Regulatory

Everest Medicines Secures Hong Kong Approval for VELSIPITY® in Ulcerative Colitis

Everest Medicines , a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeu...

April 30, 2025 | News

Akeso’s Ivonescimab Outperforms Pembrolizumab in Phase III, Wins NMPA Approval for First-Line PD-L1-Positive NSCLC

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that its globally first-in-class PD-1/VEGF bispecific antibody, ivonescimab, has re...

April 28, 2025 | News

Akeso Secures NMPA Approval for Ebdarokimab in Moderate-to-Severe Plaque Psoriasis

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that ebdarokimab, an investigational monoclonal antibody developed by the company, ...

April 21, 2025 | News

Belief BioMed and Takeda China Announce NMPA Approval of China’s First Gene Therapy for Hemophilia B

Belief BioMed ("BBM") and Takeda China jointly announced that BBM-H901 (generic name: Dalnacogene Ponparvovec Injection), has be...

April 11, 2025 | News

Lucence and HKPOS Launch Hong Kong’s First Study on Blood Test for Early Lung Cancer Detection

In a two-year collaboration with HKPOS, 600 lung cancer patients aged 45-74 in Hong Kong will be studied using Lucence's non-invasive liquid biopsy to as...

April 10, 2025 | News

China’s AIM Vaccine Set to Launch World’s First Serum-Free Rabies Vaccine Following Regulatory Acceptance

AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, announced on April 7, 2025 that the company's research and development of the se...

April 08, 2025 | News

Ascletis’ ASC30 SQ Injection Shows 36-Day Half-Life in Phase Ib Obesity Trial

-Ultra-long-acting subcutaneous (SQ) injection formulation of small molecule ASC30 demonstrated a 36-day half-life in patients with obesity, supp...

April 01, 2025 | News

Stay Connected